{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T06:33:50Z","timestamp":1759991630240,"version":"3.44.0"},"reference-count":77,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2005,7,1]],"date-time":"2005-07-01T00:00:00Z","timestamp":1120176000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2005,7,1]],"date-time":"2005-07-01T00:00:00Z","timestamp":1120176000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["amjmed.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Medicine"],"published-print":{"date-parts":[[2005,7]]},"DOI":"10.1016\/j.amjmed.2005.05.011","type":"journal-article","created":{"date-parts":[[2005,7,2]],"date-time":"2005-07-02T10:48:06Z","timestamp":1120301286000},"page":"29-38","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":35,"special_numbering":"S","title":["Antimicrobial treatment of lower respiratory tract infections in the hospital setting"],"prefix":"10.1016","volume":"118","author":[{"given":"Ronald F.","family":"Grossman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John C.","family":"Rotschafer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James S.","family":"Tan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjmed.2005.05.011_bib1","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1086\/313954","article-title":"Practice guidelines for the management of community-acquired pneumonia in adults","volume":"31","author":"Bartlett","year":"2000","journal-title":"Clin Infect Dis."},{"key":"10.1016\/j.amjmed.2005.05.011_bib2","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/S0891-5520(05)70209-9","article-title":"Hospital-acquired pneumonia","volume":"12","author":"McEachern","year":"1998","journal-title":"Infect Dis Clin North Am."},{"key":"10.1016\/j.amjmed.2005.05.011_bib3","first-page":"1184","article-title":"Chronic obstructive pulmonary disease surveillance\u2014United States, 1971\u20132000","volume":"47","author":"Mannino","year":"2002","journal-title":"Respir Care."},{"key":"10.1016\/j.amjmed.2005.05.011_bib4","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/S0149-2918(00)88310-1","article-title":"Treatment cost of acute exacerbations of chronic bronchitis","volume":"21","author":"Niederman","year":"1999","journal-title":"Clin Ther."},{"key":"10.1016\/j.amjmed.2005.05.011_bib5","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1097\/00063198-200405000-00004","article-title":"Community-acquired pneumonia in casualty","volume":"10","author":"Alves","year":"2004","journal-title":"Curr Opin Pulm Med."},{"key":"10.1016\/j.amjmed.2005.05.011_bib6","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1378\/chest.122.2.603","article-title":"Economic burden of respiratory infections in an employed population","volume":"122","author":"Birnbaum","year":"2002","journal-title":"Chest."},{"year":"2004","series-title":"Consensus Recommendations","author":"Carmichael","key":"10.1016\/j.amjmed.2005.05.011_bib7"},{"key":"10.1016\/j.amjmed.2005.05.011_bib8","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1164\/ajrccm.163.7.at1010","article-title":"Guidelines for the management of adults with community-acquired pneumonia","volume":"163","author":"Niederman","year":"2001","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.amjmed.2005.05.011_bib9","doi-asserted-by":"crossref","first-page":"165","DOI":"10.7326\/0003-4819-142-3-200502010-00006","article-title":"Outpatient care compared with hospitalization for community-acquired pneumonia","volume":"142","author":"Carratala","year":"2005","journal-title":"Ann Intern Med."},{"key":"10.1016\/j.amjmed.2005.05.011_bib10","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1001\/jama.283.6.749","article-title":"A controlled trial of a critical pathway for treatment of community-acquired pneumonia","volume":"283","author":"Marrie","year":"2000","journal-title":"JAMA"},{"key":"10.1016\/j.amjmed.2005.05.011_bib11","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1001\/archinte.158.12.1350","article-title":"Safely increasing the proportion of patients with community-acquired pneumonia treated as outpatients","volume":"158","author":"Atlas","year":"1998","journal-title":"Arch Intern Med."},{"key":"10.1016\/j.amjmed.2005.05.011_bib12","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1086\/322627","article-title":"Excessive antibiotic use for acute respiratory infections in the United States","volume":"33","author":"Gonzales","year":"2001","journal-title":"Clin Infect Dis."},{"key":"10.1016\/j.amjmed.2005.05.011_bib13","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s001340000640","article-title":"Impact of appropriateness of initial antibiotic therapy on the outcome of ventilator-associated pneumonia","volume":"27","author":"Dupont","year":"2001","journal-title":"Intensive Care Med."},{"key":"10.1016\/j.amjmed.2005.05.011_bib14","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1086\/377539","article-title":"High-dose, short-course levofloxacin for community-acquired pneumonia","volume":"37","author":"Dunbar","year":"2003","journal-title":"Clin Infect Dis."},{"key":"10.1016\/j.amjmed.2005.05.011_bib15","unstructured":"World Health Organization. World Health Organization report on infectious diseases 2000: overcoming antimicrobial resistance. WHO Web site. Available at: http:\/\/www.who.int\/infectious-disease-report\/2000\/intro.htm. Accessed June 16, 2005."},{"year":"1998","series-title":"Preventing emerging infectious diseases","key":"10.1016\/j.amjmed.2005.05.011_bib16"},{"key":"10.1016\/j.amjmed.2005.05.011_bib17","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1001\/jama.1996.03530260048030","article-title":"Prognosis and outcomes of patients with community-acquired pneumonia","volume":"275","author":"Fine","year":"1996","journal-title":"JAMA."},{"key":"10.1016\/j.amjmed.2005.05.011_bib18","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1093\/jac\/49.1.31","article-title":"Antibiotic therapy of community respiratory tract infections","volume":"49","author":"Ball","year":"2002","journal-title":"J Antimicrob Chemother."},{"key":"10.1016\/j.amjmed.2005.05.011_bib19","doi-asserted-by":"crossref","first-page":"iv1","DOI":"10.1136\/thx.56.suppl_4.iv1","article-title":"BTS guidelines for the management of community acquired pneumonia in adults","volume":"56","year":"2001","journal-title":"Thorax"},{"key":"10.1016\/j.amjmed.2005.05.011_bib20","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1086\/380488","article-title":"Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults","volume":"37","author":"Mandell","year":"2003","journal-title":"Clin Infect Dis."},{"key":"10.1016\/j.amjmed.2005.05.011_bib21","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1001\/archinte.164.6.637","article-title":"Timing of antibiotic administration and outcomes for Medicare patients hospitalized with community-acquired pneumonia","volume":"164","author":"Houck","year":"2004","journal-title":"Arch Intern Med."},{"key":"10.1016\/j.amjmed.2005.05.011_bib22","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1164\/rccm.200405-644ST","article-title":"Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia","volume":"171","year":"2005","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.amjmed.2005.05.011_bib23","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.1086\/378406","volume":"38","author":"Fogarty","year":"2004","journal-title":"Clin Infect Dis."},{"key":"10.1016\/j.amjmed.2005.05.011_bib24","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1016\/S0149-2918(02)80034-0","article-title":"A multicenter, open-label, randomized comparison of levofloxacin and azithromycin plus ceftriaxone in hospitalized adults with moderate to severe community-acquired pneumonia","volume":"24","author":"Frank","year":"2002","journal-title":"Clin Ther."},{"issue":"suppl 1","key":"10.1016\/j.amjmed.2005.05.011_bib25","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1086\/378404","article-title":"Current challenges in the treatment of community-acquired pneumonia","volume":"38","author":"File","year":"2004","journal-title":"Clin Infect Dis"},{"year":"2004","series-title":"Levaquin","key":"10.1016\/j.amjmed.2005.05.011_bib26"},{"year":"2004","series-title":"Rocephin","key":"10.1016\/j.amjmed.2005.05.011_bib27"},{"key":"10.1016\/j.amjmed.2005.05.011_bib28","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.ijantimicag.2004.07.013","article-title":"Levofloxacin versus ceftriaxone plus clarithromycin in the treatment of adults with community-acquired pneumonia requiring hospitalization","volume":"25","author":"Querol-Ribelles","year":"2005","journal-title":"Int J Antimicrob Agents."},{"year":"2005","series-title":"Safety and efficacy of moxifloxacin vs levofloxacin in elderly patients with community-acquired pneumonia (CAP)","author":"Anzueto","key":"10.1016\/j.amjmed.2005.05.011_bib29"},{"key":"10.1016\/j.amjmed.2005.05.011_bib30","unstructured":"Center for Drug Evaluation and Research. Moxifloxacin hydrochloride (Avelox) I.V. solution statistical review. Available at: http:\/\/www.fda.gov\/cder\/foi\/nda\/2001\/21277_Avelox.htm. Accessed March 25, 2005."},{"issue":"suppl 3","key":"10.1016\/j.amjmed.2005.05.011_bib31","doi-asserted-by":"crossref","first-page":"S159","DOI":"10.1086\/421354","article-title":"Clinical efficacy of newer agents in short-duration therapy for community-acquired pneumonia","volume":"39","author":"File","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.amjmed.2005.05.011_bib32","unstructured":"World Health Organization. WHO global strategy for containment of antimicrobial resistance. WHO Web site. Available at: www.who.int\/entity\/drugresistance\/WHO_Global_Strategy_English.pdf. Accessed January 28, 2005."},{"key":"10.1016\/j.amjmed.2005.05.011_bib33","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1007\/BF02310353","article-title":"Efficacy and safety of azithromycin versus benzylpenicillin or erythromycin in community-acquired pneumonia","volume":"14","author":"Bohte","year":"1995","journal-title":"Eur J Clin Microbiol Infect Dis."},{"key":"10.1016\/j.amjmed.2005.05.011_bib34","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1185\/030079904125003610","article-title":"Comparison of hospitalization rates in patients with community-acquired pneumonia treated with telithromycin for 5 or 7 days or clarithromycin for 10 days","volume":"20","author":"Tellier","year":"2004","journal-title":"Curr Med Res Opin."},{"key":"10.1016\/j.amjmed.2005.05.011_bib35","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1185\/030079904125003304","article-title":"Efficacy of 750-mg, 5-day levofloxacin in the treatment of community-acquired pneumonia caused by atypical pathogens","volume":"20","author":"Dunbar","year":"2004","journal-title":"Curr Med Res Opin."},{"key":"10.1016\/j.amjmed.2005.05.011_bib36","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0149-2918(00)88266-1","article-title":"Expanded activity and utility of the new fluoroquinolones","volume":"21","author":"Blondeau","year":"1999","journal-title":"Clin Ther."},{"key":"10.1016\/j.amjmed.2005.05.011_bib37","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1159\/000071142","article-title":"Comparative in vitro activity of three fluoroquinolones against clinical isolates by E test","volume":"49","author":"Madhusudhan","year":"2003","journal-title":"Chemotherapy."},{"key":"10.1016\/j.amjmed.2005.05.011_bib38","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/S0149-2918(03)80091-7","article-title":"Levofloxacin compared with imipenem\/cilastatin followed by ciprofloxacin in adult patients with nosocomial pneumonia","volume":"25","author":"West","year":"2003","journal-title":"Clin Ther."},{"issue":"Suppl 2","key":"10.1016\/j.amjmed.2005.05.011_bib39","doi-asserted-by":"crossref","first-page":"S123","DOI":"10.1086\/426192","article-title":"Levofloxacin for treatment of ventilator-associated pneumonia","volume":"40","author":"Shorr","year":"2005","journal-title":"Clin Infect Dis."},{"key":"10.1016\/j.amjmed.2005.05.011_bib40","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1164\/ajrccm.162.2.9909095","article-title":"Short-course empiric antibiotic therapy for patients with pulmonary infiltrates in the intensive care unit","volume":"162","author":"Singh","year":"2000","journal-title":"Am J Respir Crit Care Med."},{"issue":"suppl B","key":"10.1016\/j.amjmed.2005.05.011_bib41","first-page":"3B","article-title":"Canadian guidelines for the management of acute exacerbations of chronic bronchitis","volume":"10","author":"Balter","year":"2003","journal-title":"Can Respir J"},{"issue":"suppl","key":"10.1016\/j.amjmed.2005.05.011_bib42","doi-asserted-by":"crossref","first-page":"310S","DOI":"10.1378\/chest.112.6_Supplement.310S","article-title":"Guidelines for the treatment of acute exacerbations of chronic bronchitis","volume":"112","author":"Grossman","year":"1997","journal-title":"Chest"},{"key":"10.1016\/j.amjmed.2005.05.011_bib43","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1001\/jama.283.12.1583","article-title":"Comparison of ciprofloxacin (7 days) and trimethoprim-sulfamethoxazole (14 days) for acute uncomplicated pyelonephritis in women","volume":"283","author":"Talan","year":"2000","journal-title":"JAMA."},{"issue":"Suppl 3","key":"10.1016\/j.amjmed.2005.05.011_bib44","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1016\/S1098-3597(03)90024-X","article-title":"Resistance issues and community-acquired respiratory infections","author":"Sahm","year":"2003","journal-title":"Clin Cornerstone"},{"year":"2004","series-title":"Data on file","key":"10.1016\/j.amjmed.2005.05.011_bib45"},{"key":"10.1016\/j.amjmed.2005.05.011_bib46","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1128\/AAC.48.6.2101-2107.2004","article-title":"High prevalence of antimicrobial resistance among clinical Streptococcus pneumoniae isolates in Asia (an ANSORP study)","volume":"48","author":"Song","year":"2004","journal-title":"Antimicrob Agents Chemother."},{"key":"10.1016\/j.amjmed.2005.05.011_bib47","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1128\/AAC.45.4.1037-1042.2001","article-title":"Need for annual surveillance of antimicrobial resistance in Streptococcus pneumoniae in the United States","volume":"45","author":"Sahm","year":"2001","journal-title":"Antimicrob Agents Chemother."},{"key":"10.1016\/j.amjmed.2005.05.011_bib48","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1128\/AAC.43.10.2504","article-title":"Prevalence of antimicrobial resistance in respiratory tract isolates of Streptococcus pneumoniae","volume":"43","author":"Zhanel","year":"1999","journal-title":"Antimicrob Agents Chemother."},{"key":"10.1016\/j.amjmed.2005.05.011_bib49","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1093\/jac\/45.suppl_2.19","article-title":"Optimizing economic outcomes in antibiotic therapy of patients with acute bacterial exacerbations of chronic bronchitis","volume":"45","author":"Pechere","year":"2000","journal-title":"J Antimicrob Chemother."},{"key":"10.1016\/j.amjmed.2005.05.011_bib50","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1378\/chest.113.6.1542","article-title":"Infective exacerbations of chronic bronchitis","volume":"113","author":"Eller","year":"1998","journal-title":"Chest."},{"key":"10.1016\/j.amjmed.2005.05.011_bib51","doi-asserted-by":"crossref","first-page":"4S","DOI":"10.1016\/S0002-9343(01)01025-7","article-title":"Frequency of pathogen occurrence and antimicrobial susceptibility among community-acquired respiratory tract infections in the respiratory surveillance program study","volume":"111","author":"Pfaller","year":"2001","journal-title":"Am J Med."},{"year":"2004","series-title":"Tequin [package insert]","key":"10.1016\/j.amjmed.2005.05.011_bib52"},{"issue":"Suppl 3","key":"10.1016\/j.amjmed.2005.05.011_bib53","doi-asserted-by":"crossref","first-page":"S29","DOI":"10.1016\/S1098-3597(03)90027-5","article-title":"Safety and tolerability of fluoroquino-lones","author":"Sprandel","year":"2003","journal-title":"Clin Cornerstone"},{"year":"2004","series-title":"Avelox [package insert]","key":"10.1016\/j.amjmed.2005.05.011_bib54"},{"year":"2004","series-title":"Factive [package insert]","key":"10.1016\/j.amjmed.2005.05.011_bib55"},{"year":"2004","series-title":"Ketek [package insert]","key":"10.1016\/j.amjmed.2005.05.011_bib56"},{"key":"10.1016\/j.amjmed.2005.05.011_bib57","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1001\/jama.287.17.2215","article-title":"Timing of new black box warnings and withdrawals for prescription medications","volume":"287","author":"Lasser","year":"2002","journal-title":"JAMA."},{"key":"10.1016\/j.amjmed.2005.05.011_bib58","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1111\/j.1742-1241.2003.tb10543.x","article-title":"Telithromycin","volume":"57","author":"Lorenz","year":"2003","journal-title":"Int J Clin Pract."},{"key":"10.1016\/j.amjmed.2005.05.011_bib59","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1056\/NEJMoa040582","article-title":"Oral erythromycin and the risk of sudden death from cardiac causes","volume":"351","author":"Ray","year":"2004","journal-title":"N Engl J Med."},{"key":"10.1016\/j.amjmed.2005.05.011_bib60","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.2337\/diacare.25.9.1659-a","article-title":"Severe hypoglycemia from clarithromycin-sulfonylurea drug interaction","volume":"25","author":"Bussing","year":"2002","journal-title":"Diabetes Care."},{"key":"10.1016\/j.amjmed.2005.05.011_bib61","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1177\/106002809703100918","article-title":"Digoxin-macrolide drug interaction","volume":"31","author":"Bizjak","year":"1997","journal-title":"Ann Pharmacother."},{"key":"10.1016\/j.amjmed.2005.05.011_bib62","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1007\/BF01700406","article-title":"Clarithromycin versus amoxicillin-clavulanic acid in the treatment of community-acquired pneumonia","volume":"16","author":"Genne","year":"1997","journal-title":"Eur J Clin Microbiol Infect Dis."},{"key":"10.1016\/j.amjmed.2005.05.011_bib63","doi-asserted-by":"crossref","first-page":"2588","DOI":"10.1001\/jama.290.19.2588","article-title":"Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults","volume":"290","author":"Chastre","year":"2003","journal-title":"JAMA."},{"key":"10.1016\/j.amjmed.2005.05.011_bib64","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1001\/jama.286.1.49","article-title":"Effect of short-course, high-dose amoxicillin therapy on resistant pneumococcal carriage","volume":"286","author":"Schrag","year":"2001","journal-title":"JAMA."},{"key":"10.1016\/j.amjmed.2005.05.011_bib65","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/S0924-8579(02)00360-6","article-title":"Does short-course antibiotic therapy better meet patient expectations?","volume":"21","author":"Perez-Gorricho","year":"2003","journal-title":"Int J Antimicrob Agents."},{"issue":"Suppl 3","key":"10.1016\/j.amjmed.2005.05.011_bib66","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1016\/S1098-3597(03)90026-3","article-title":"A new dosing paradigm","author":"File","year":"2003","journal-title":"Clin Cornerstone."},{"key":"10.1016\/j.amjmed.2005.05.011_bib67","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1001\/jama.279.5.365","article-title":"Low dosage and long treatment duration of beta-lactam","volume":"279","author":"Guillemot","year":"1998","journal-title":"JAMA."},{"key":"10.1016\/j.amjmed.2005.05.011_bib68","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1378\/chest.119.4.1114","article-title":"Steady-state plasma and intrapulmonary concentrations of levofloxacin and ciprofloxacin in healthy adult subjects","volume":"119","author":"Gotfried","year":"2001","journal-title":"Chest."},{"key":"10.1016\/j.amjmed.2005.05.011_bib69","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S0732-8893(02)00417-0","article-title":"Pharmacodynamics of 750 mg and 500 mg doses of levofloxacin against ciprofloxacin-resistant strains of Streptococcus pneumoniae","volume":"44","author":"Lister","year":"2002","journal-title":"Diagn Microbiol Infect Dis."},{"key":"10.1016\/j.amjmed.2005.05.011_bib70","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1093\/jac\/43.1.79","article-title":"Pharmacodynamics of levofloxacin and ciprofloxacin against Streptococcus pneumoniae","volume":"43","author":"Lister","year":"1999","journal-title":"J Antimicrob Chemother."},{"year":"2003","series-title":"Data on file","key":"10.1016\/j.amjmed.2005.05.011_bib71"},{"issue":"suppl 7A","key":"10.1016\/j.amjmed.2005.05.011_bib72","doi-asserted-by":"crossref","first-page":"45S","DOI":"10.1016\/j.amjmed.2005.05.013","article-title":"Treatment of rhinosinusitis in the outpatient setting","volume":"118","author":"Poole","year":"2005","journal-title":"Am J Med."},{"issue":"suppl 7A","key":"10.1016\/j.amjmed.2005.05.011_bib73","doi-asserted-by":"crossref","first-page":"39S","DOI":"10.1016\/j.amjmed.2005.05.012","article-title":"Appropriate outpatient treatment of acute bacterial exacerbations of chronic bronchitis","volume":"118","author":"Martinez","year":"2005","journal-title":"Am J Med."},{"key":"10.1016\/j.amjmed.2005.05.011_bib74","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1378\/chest.113.1.131","article-title":"A 1-year community-based health economic study of ciprofloxacin vs usual antibiotic treatment in acute exacerbations of chronic bronchitis","volume":"113","author":"Grossman","year":"1998","journal-title":"Chest."},{"key":"10.1016\/j.amjmed.2005.05.011_bib75","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1185\/030079904X2556","article-title":"Clinical implications of 750 mg, 5-day levofloxacin for the treatment of community-acquired pneumonia","volume":"20","author":"File","year":"2004","journal-title":"Curr Med Res Opin."},{"year":"2004","series-title":"Pharmacoeconomic and clinical implications of 750-mg, 5-day levofloxacin for community-acquired pneumonia (CAP)","author":"Milkovich","key":"10.1016\/j.amjmed.2005.05.011_bib76"},{"key":"10.1016\/j.amjmed.2005.05.011_bib77","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1185\/030079904125003223","article-title":"Drug costs and bacterial susceptibility after implementing a single-fluoroquinolone use policy at a university hospital","volume":"20","author":"Rapp","year":"2004","journal-title":"Curr Med Res Opin."}],"container-title":["The American Journal of Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002934305003852?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002934305003852?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T08:38:42Z","timestamp":1757579922000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002934305003852"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,7]]},"references-count":77,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2005,7]]}},"alternative-id":["S0002934305003852"],"URL":"https:\/\/doi.org\/10.1016\/j.amjmed.2005.05.011","relation":{},"ISSN":["0002-9343"],"issn-type":[{"type":"print","value":"0002-9343"}],"subject":[],"published":{"date-parts":[[2005,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antimicrobial treatment of lower respiratory tract infections in the hospital setting","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjmed.2005.05.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2005 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}